XPH ETF Analysis: S&P Pharmaceuticals | NYSE
Healthcare Equity | NYSE, USA | Market Cap: 477m USD | 12M Return: 38.6% | US78464A7220 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.79M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The SPDR® S&P Pharmaceuticals ETF (XPH) seeks to track the performance of the S&P Pharmaceuticals Select Industry Index using a sampling strategy. The fund invests substantially all of its assets-at least 80% of total assets-in the securities that make up the index, which represents the pharmaceuticals segment of the broader S&P Total Market Index (S&P TMI).
The pharmaceuticals sector encompasses companies engaged in the research, development, manufacturing, and commercialization of drugs and medications. By employing a sampling approach rather than full replication, the fund can mirror the indexs performance and risk characteristics without needing to hold every constituent security, which can help reduce trading costs and administrative complexity.
- IRA Medicare drug price negotiations expand annually
- GLP-1 obesity drug sales surge across pharma
- Patent cliffs expose major drug franchises to generics
As of November 11, 2026, the stock is trading at USD 67.93 with a total of 174,106 shares traded. Over the past week, the price has changed by +5.65%, over one month by +6.12%, over three months by -3.05% and over the past year by +38.61%.
Current recommended Stop Loss: 64.60 (which is 4.9% or 2 ATR below the current price).
S&P Pharmaceuticals has no consensus analysts rating.